Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Innovation Action · Running

UNLOOC Unlocking data content of Organ-On-Chips

Coordinator
Microfluidic Chipshop GmbH, Germany
Runs
1 May 2024 to 30 April 2027
Status
Running
EU funding
€14.1m
Total cost
€49.2m
Partners
54 organisations in 10 countries
Type
Innovation Action
Grant agreement
101140192

What the project is doing

In the project's own words, from its summary on CORDIS.

The launch of a novel drug to the market is preceded by clinical testing and validation both on animal in vitro and in vivo models. Animal models used in drug development have known methodological drawbacks leading to the failure of drugs. Further, animal tests are associated with ethical issues. Moreover, a strong bias in in-human testing still overlooks major population groups e.g. children, women, different ethical groups.

It is estimated that 197,000 deaths per year in the EU are caused by Adverse Drug Reactions (ADRs) and the total cost to society of ADRs is €79 billion. The emerging Organ-on-Chip (OOC) field, an alternative to animal test, brings great potential for safe testing and validation: An OOC-systems consists of a 3D-microstructured channel network embedded on a small plastic device that simulates the mechanics and physiological response of an entire organ or organs.

Project UNLOOC will develop, optimize, and validate a multitude of ECS-based tools to build OOC-models to replace animal and in-human testing. UNLOOC aims to combine three important characteristics for routine use of OOC models, i.e platforms that combine ECS-based technologies with established biological material, capitalize on AI, parallelized test set-ups allowing efficient high-throughput demands, and standardized procedures enabling reliable results.

UNLOOC will develop ECS-based hardware and software tools and validate them in five Use Cases (UCs) performed in 10 European countries. The applications developed and validated will be used by academia and pharma industry to drive drug development, create cosmetics without animal test, personalized medicine and gain new insights into disease. Given the large OOC market, these solutions have great economic value, on average it would result in cost reduction of up to $169M and $706M per new drug reaching the market and will put Europe at the forefront of this booming research field (see impact section for details).

Who is involved

OrganisationCityCountryRole
Microfluidic Chipshop GmbHJenaGermanyCoordinator
Interuniversitair Micro-Electronica CentrumLeuvenBelgiumParticipant
Alveolix AGBernSwitzerlandAssociatedpartner
Csem Centre Suisse D'electronique Et De Microtechnique SA - Recherche Et DeveloppementNeuchatelSwitzerlandAssociatedpartner
Haute Ecole Specialisee De Suisse OccidentaleDelemontSwitzerlandAssociatedpartner
Insphero AGSchlierenSwitzerlandAssociatedpartner
Liom Health AGPfäffikonSwitzerlandAssociatedpartner
Ost - Ostschweizer FachhochschuleRapperswilSwitzerlandAssociatedpartner
Carl Zeiss Microscopy GmbHJenaGermanyParticipant
Esqlabs GmbHSaterlandGermanyParticipant
European Infrastructure of Open Screening Platforms for Chemical Biology European Research Infrastucture Consortium (eu-Openscreen Eric)BerlinGermanyParticipant
Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eVMunchenGermanyParticipant
Jobst Technologies GmbHFreiburg Im BreisgauGermanyParticipant
LipotypeDresdenGermanyParticipant
Multi Channel Systems Mcs GmbHReutlingenGermanyParticipant
Nuromedia GmbHKolnGermanyParticipant
Stelar Security Technology Law Research UG (haftungsbeschrankt) GmbHHamburgGermanyParticipant
Technische Universitaet BraunschweigBraunschweigGermanyParticipant
Beonchip SLZaragozaSpainParticipant
Cytes Biotechnologies SLBarcelonaSpainParticipant
Ebers Medical Technology SLZaragozaSpainParticipant
Fundacio Institut De Bioenginyeria De CatalunyaBarcelonaSpainParticipant
Fundacion De La Comunidad Valenciana Centro De Investigacion Principe FelipeValenciaSpainParticipant
Fundacion Instituto De Investigacion Sanitaria AragonZaragozaSpainParticipant
I+med S CoopVitoria-GasteizSpainParticipant
Ihs Weigling Sociedad LimitadaErandio VizcayaSpainParticipant
Universidad De Santiago De CompostelaSantiago De CompostelaSpainParticipant
Universidad De ZaragozaZaragozaSpainParticipant
Universidad Del Pais Vasco/ Euskal Herriko UnibertsitateaLeioaSpainParticipant
Viscofan Espana S.l.TajonarSpainParticipant
Hun-Ren Energiatudomanyi KutatokozpontBudapestHungaryParticipant
HUN-REN Energiatudomanyi KutatokozpontBudapestHungaryParticipant
University College Cork - National University of Ireland, CorkCorkIrelandParticipant
Okolab SRLOttaviano - NaItalyParticipant
Universita Degli Studi Di PaviaPaviaItalyParticipant
Abbvie Ireland Nl BVZwolleNetherlandsParticipant
Core Life Analytics BV'S-HertogenboschNetherlandsParticipant
Demcon Curix BVEnschedeNetherlandsThird party
Demcon Life Sciences & Health Enschede BVEnschedeNetherlandsThird party
Demcon Sync Biosystems BVEnschedeNetherlandsParticipant
Lionix International B.v.EnschedeNetherlandsParticipant
Locsense B.v.EnschedeNetherlandsParticipant
Micronit BVEnschedeNetherlandsParticipant
Nederlandse Organisatie Voor Toegepast Natuurwetenschappelijk Onderzoek TNODen HaagNetherlandsParticipant
Philips Electronics Nederland BVEindhovenNetherlandsParticipant
Stichting IMEC NederlandEindhovenNetherlandsParticipant
Technische Universiteit DelftDelftNetherlandsParticipant
Universiteit MaastrichtMaastrichtNetherlandsParticipant
Xiver Mems Foundry BVEindhovenNetherlandsParticipant
Inesc Id Instituto De Engenhariade Sistemas E Computadores Investigacao E Desenvolvimento Em LisboaLisboaPortugalParticipant
Inesc Microsistemas E Nanotecnologias - Instituto De Engenharia De Sistemas E Computadores Para Os Microsistemas E AS NanotecnologiasLisboaPortugalParticipant
Silicongate LdaPortoPortugalParticipant
Dds Diagnostic SRLBucurestiRomaniaParticipant
Institutul National De Cercetaredezvoltare Pentru MicrotehnologieVoluntariRomaniaParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI